Editas Medicine (EDIT) Non-Current Deffered Revenue (2015 - 2025)

Editas Medicine (EDIT) has 11 years of Non-Current Deffered Revenue data on file, last reported at $44.5 million in Q4 2025.

• Quarterly Non-Current Deffered Revenue fell 17.89% year-over-year to $44.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $44.5 million (down 17.89% YoY) and the FY2025 annual result came in at $44.5 million, down 17.89% from the prior year.
• Non-Current Deffered Revenue declined to $44.5 million in Q4 2025 per EDIT's latest filing, from $54.2 million in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $68.9 million in Q2 2022 and bottomed at $44.5 million in Q4 2025.
• The 5-year median for Non-Current Deffered Revenue is $58.7 million (2021), against an average of $57.8 million.
• The widest annual swing landed in 2021, when Non-Current Deffered Revenue sank 60.1%; it then gained 24.75% in 2022.
• Tracing EDIT's Non-Current Deffered Revenue over 5 years: stood at $60.9 million in 2021, then dropped by 0.36% to $60.7 million in 2022, then changed by 0.0% to $60.7 million in 2023, then slipped by 10.65% to $54.2 million in 2024, then decreased by 17.89% to $44.5 million in 2025.
• Per Business Quant, the three latest EDIT Non-Current Deffered Revenue figures stand at $44.5 million (Q4 2025), $54.2 million (Q3 2025), and $54.2 million (Q2 2025).

Peer Comparison